# Gabriel N. Hortobágyi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gabriel-n-hortobagyi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 141,209 |
| Field | Breast Cancer Treatment Studies |
| h-index | 187 |
| i10-index | 937 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5018617106 |
| ORCID iD | https://orcid.org/0000-0002-4873-4412 |
| Works | 1,905 |

## Researcher papers

Showing 12 of 23.

- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation](https://scholariq.org/papers/future-of-cancer-incidence-in-the-united-states-burdens-upon-an-aging-changing/)
- [Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy](https://scholariq.org/papers/measurement-of-residual-breast-cancer-burden-to-predict-survival-after/)
- [Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial](https://scholariq.org/papers/prognostic-and-predictive-value-of-the-21-gene-recurrence-score-assay-in/)
- [Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy](https://scholariq.org/papers/clinical-course-of-breast-cancer-patients-with-complete-pathologic-primary-tumor/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual](https://scholariq.org/papers/breast-cancer-major-changes-in-the-american-joint-committee-on-cancer-eighth/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics](https://scholariq.org/papers/characterization-of-a-naturally-occurring-breast-cancer-subset-enriched-in/)
- [Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](https://scholariq.org/papers/pharmacogenomic-predictor-of-sensitivity-to-preoperative-chemotherapy-with/)
- [Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update](https://scholariq.org/papers/recommendations-from-an-international-expert-panel-on-the-use-of-neoadjuvant/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.